PHARMACY

Amneal named Generics bulletin’s Company of the Year

BY David Salazar

BRIDGEWATER, N.J. — Amneal Pharmaceuticals was named Company of the Year by Generics bulletin at this year’s Global Generics and Biosimilars Awards. This is the second year in a row that the industry newsletter has honored Amneal.
 
“Amneal prides itself in staying true to its core values: integrity, accountability, hard work, and collaboration,” Amneal co-CEO and chairman Chirag Patel said. “Winning this award is proof that acting on our values and executing our growth strategy has enabled us to continue to deliver on our promise of providing high-quality, affordable medicines for patients around the world.”
 
Amneal is the United States’ seventh largest generics manufacture by prescriptions.. The company’s annual sales are nearly $1 billion and it now has more than 86 FDA-approved molecules in its portfolio. 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Exclusive webinar: “Chronic Care and Retail Health,” presented by DSN/CCA

BY DSN STAFF

More and more, health systems are seeking to manage chronic disease rather than just treat it — and they are looking for partners to make it happen.
 
To help key healthcare stakeholders and industry professionals better understand how retail clinics and hospital and health systems are partnering to provide coordinated care that places the patient at the center of the model, Drug Store News and and the Convenient Care Association will host an exclusive webinar, “Chronic Care and Retail Health,” presented by Eileen Myers, MPH, RDN VP, affiliations and patient centered strategies, The Little Clinic. 
 
Slated for Wednesday, December 2, “Chronic Care and Retail Health,” is part of the six-part, DSN/CCA Retail Healthcare Webinar Series. Click to register.
 
The Dec. 2 webinar will explore lessons learned from the retail clinic industry’s focus on patient satisfaction; effective methods of care that center on the whole patient in a coordinated fashion; and how clearly defined health system and patient goals can facilitate a better understanding and measurement of the business impact of managing chronic diseases like diabetes.
 

“Retail health clinics in traditional retail chain drug stores have become a critical boardroom conversation and a key platform to transform traditional brick and mortar retailers into integrated healthcare providers,” said Wayne Bennett, group publisher of Drug Store News.

“This educational platform is unique because the webinars are specifically designed for healthcare leadership and professionals and showcase the value proposition of the retail health industry,” said Tine Hansen-Turton, executive director of the Convenient Care Association.

Moderated by Drug Store News editor Rob Eder, the DSN/CCA Retail Healthcare Webinar Series, kicks off Tuesday, Nov. 3, and includes:

  • Integrated health care throughout the store, presented by Web Golinkin, CEO Rite Aid Rediclinic and Health Dialog.
  • The role of telehealth in retail health care, presented by Tobias Barker, VP, medical operations, MinuteClinic.
  • Partnerships in Population Health, presented by Patrick Carroll, MD, medical director for Walgreens Health Care Clinic.
  • Chronic Care and Retail Health, presented by Eileen Myers, MPH, RDN, VP, affiliations and patient-centered strategies, The Little Clinic.      
  • Emerging Payment Models, presented by S. Lawrence Kocot, principal and national leader of the Center for Healthcare Regulatory Insight, KPMG.

The DSN/CCA Retail Healthcare Webinar Series runs through December, with archived sessions available for one year at DrugStoreNews.com. For the complete webinar schedule, detailed session descriptions and registration information, click here.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA approves new pancreatic cancer treatment

BY DSN STAFF

SILVER SPRING, Md. — The Food and Drug Administrtion on Thursday announced that it had approved Merrimack Pharmaceuticals’ Onivyde (irinotecan liposome) injection. The drug is a treatment for metastatic pancreatic cancer in combination with fluoracil and leucovorin. 
 
“Many FDA staff who review drug applications are clinicians as well, so it’s especially rewarding when we are able to expedite access to new treatments for patients with unmet needs,” said Dr. Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “By using the Priority Review designation for the application for Onivyde, patients will have earlier access to a drug that helps extend survival.”
 
Onivyde includes a boxed warning about potential risks of sever neutropenia and diarrhea among patients being treated with it. 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?